Short answer
Retatrutide is a synthetic peptide that activates three receptors - GIP, GLP-1 and glucagon - in one molecule. It is a research tool for studying multi-receptor incretin signaling. PEPMAKE sells it as a lyophilized research powder for laboratory use only.
What is retatrutide?
Retatrutide is a triple receptor agonist. Where earlier peptides activate one receptor (mono-agonist) or two (dual agonist), retatrutide combines activity at three receptors:
This design lets researchers ask questions about multi-receptor signaling that would be difficult with separate peptides [1].
Research background
The Lancet published a randomized phase 2 trial of retatrutide in 2023, which is the most-cited clinical reference for the compound [2]. For laboratory researchers, the peptide is relevant as:
Key facts at a glance
| Property | Detail |
|---|---|
| Type | Triple GIP/GLP-1/glucagon receptor agonist |
| Receptor targets | GIP, GLP-1, glucagon |
| Research themes | Multi-receptor metabolic signaling |
| Typical form | Lyophilized powder |
| Purity expectation | 99%+ by HPLC |
Buying checklist
Browse Retatrutide product options or the GLP-1 research category.
FAQ
What is retatrutide?
A triple receptor agonist targeting GIP, GLP-1 and glucagon receptors.
Why is a triple agonist interesting?
It combines three receptor activities in one molecule for multi-receptor studies.
How is it studied?
Receptor pharmacology, cell signaling and metabolic research models.
Is it for human use?
No, laboratory research use only.